432c57e1-e191-4fdc-9aaa-53e460c82acc
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 57.7494866529774
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.390
- HEDGEHOG_SIGNALING+0.290
- HYPOXIA+0.220
- PROTEIN_SECRETION+0.120
- COAGULATION+0.110
- BILE_ACID_METABOLISM+0.100
- XENOBIOTIC_METABOLISM+0.100
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.090
- MYOGENESIS+0.020
- KRAS_SIGNALING_DN+0.010
Top 10 suppressed
- E2F_TARGETS-0.570
- INTERFERON_ALPHA_RESPONSE-0.520
- G2M_CHECKPOINT-0.500
- INTERFERON_GAMMA_RESPONSE-0.480
- IL6_JAK_STAT3_SIGNALING-0.460
- ALLOGRAFT_REJECTION-0.370
- INFLAMMATORY_RESPONSE-0.350
- OXIDATIVE_PHOSPHORYLATION-0.310
- MYC_TARGETS_V1-0.290
- PI3K_AKT_MTOR_SIGNALING-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3L-02834 | — | cohortA1 | 0.822 |
| 2 | e3d71c3f-4e56-45fa-be88-2cf444b70a5c | — | — | 0.810 |
| 3 | C3L-02165 | — | cohortA2 | 0.797 |
| 4 | TCGA-CN-4737-01A-01R-1436-07 | — | — | 0.788 |
| 5 | MNG703 | — | — | 0.788 |
| 6 | TCGA-CV-7103-01A-21R-2016-07 | — | — | 0.782 |
| 7 | TCGA-A7-A0D9-01A-31R-A056-07 | — | B | 0.781 |
| 8 | 8a25dfb0-edd0-4a44-9a6b-8f3f761b940c | — | — | 0.780 |
| 9 | SRR25617895 | — | B | 0.780 |
| 10 | 35c6ff25-753c-4ebe-bbe7-2e7105d052e8 | — | — | 0.776 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 10 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.290 | Inavolisib | — uncovered |
| HYPOXIA | 0.220 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.120 | Remibrutinib | — uncovered |
| COAGULATION | 0.110 | Binimetinib | — uncovered |
| BILE_ACID_METABOLISM | 0.100 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.090 | Inavolisib | — uncovered |
| MYOGENESIS | 0.020 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.010 | Remibrutinib | — uncovered |